Impact of Preoperative Single Corticosteroid Flash on Morbidity After Colorectal Resection: Monocentric Prospective Pilot Study

Overview

Complications due to infection after colorectal surgery are frequent, affecting up to 25% of patients. Infection increases mortality, lengthens hospital stays, increases costs and decreases long term survival for cancer patients. Perioperative inflammation leads to hypercatabolism, denutrition and immunosuppression, all of which are associated to postoperative infection. Data from various sources suggests that modulating perioperative inflammatory response through the injection of corticosteroids would benefit the patient by reducing the number of postoperative complications after major surgery. Pre- or perioperative intravenous administration of a single corticosteroid flash is a means of modulating systemic inflammation that has been suggested for numerous types of surgeries, including pancreatic surgery. The objective of this study is to assess whether a preoperative single corticosteroid flash (methylprednisolone: 20 mg/kg IV at anesthetic induction) reduces the risk of serious complications after elective colorectal surgery.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: September 30, 2021

Interventions

  • Drug: injection of methylprednisolone at anesthetic induction
    • intravenous administration : 20 mg/kg, over 30 minutes at anesthetic induction
  • Biological: Blood samples
    • Blood samples (D0, D1, D2, D3, D4)

Clinical Trial Outcome Measures

Primary Measures

  • Frequency of postoperative complications, occuring up to 30 days post-operatively
    • Time Frame: Day 30

Participating in This Clinical Trial

Inclusion Criteria

  • Adult patient – Patient undergoing elective colorectal surgery (diverticulitis, malignant or benign tumor, inflammatory intestinal disease, re-establishing continuity, endometriosis, or other) – Bowel continuity is restored immediately after surgery, with or without a protective stoma. – Patient with proper understanding who has been informed about the study, and who has consented to being part of the study Exclusion Criteria:

  • Adult under guardianship – Patient who is not covered under the national health system – Women who are pregnant or breastfeeding – Colorectal resection with concomitant hyperthermic intraperitoneal chemotherapy – Patient under long term corticosteroid therapy – Preoperative natremia > 147 mmol/L – Hypokalemia (< 3,3 mmol/L) – Patient with a contraindication to Methylprednisolone Mylan® : – Active infection – Active viral disease (namely hepatitis, herpes, varicella, shingles), – A psychotic condition that is not currently treated with medication, – Vaccination with a live vaccine or live attenuated within the last 3 months, – Hypersensitivity to methylprednisolone or to any of the excipients found in Methylprednisolone Mylan®

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Centre Hospitalier Universitaire Dijon
  • Provider of Information About this Clinical Study
    • Sponsor

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.